Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10412903 | 1.00 | TLR8 (0.50) | TLR8CNR2TP53OXER1MAPT | |
| SCHEMBL10693099 | 1.00 | TLR8 (0.50) | TLR8CNR2TP53OXER1MAPT | |
| SCHEMBL21278119 | 0.98 | TLR8 (0.49) | TLR8CNR2TP53OXER1CNR1 | |
| SCHEMBL10413631 | 0.89 | TLR8 (0.49) | TLR8CNR2TP53OXER1 | |
| SCHEMBL3847993 | 0.87 | OXER1 (0.51) | TLR8CNR2TP53OXER1CNR1 | |
| SCHEMBL6211295 | 0.86 | CNR2 (0.47) | TLR8CNR2TP53OXER1CNR1 | |
| SCHEMBL10413247 | 0.82 | MEN1 (0.56) | TLR8CNR2TP53MAPTSMN1; SMN2 | |
| SCHEMBL11153101 | 0.82 | MEN1 (0.56) | TLR8CNR2TP53MAPTSMN1; SMN2 | |
| SCHEMBL11607923 | 0.82 | MEN1 (0.56) | TLR8CNR2TP53MAPTSMN1; SMN2 | |
| SCHEMBL4212491 | 0.82 | MEN1 (0.56) | TLR8CNR2TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | CUBIST PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | TLR8 3157/4885CNR2 4752/4885TP53 3982/4885 |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | VIP, DNPEP, PREP | TLR8 3157/4885CNR2 4752/4885TP53 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.